For the first-line treatment of NSCLC, the intercalated combination of chemotherapy and EGFR TKIs showed improved PFS compared to chemotherapy alone and improved ORR and DCR compared to EGFR TKI monotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.